Bubar Marcy J, Cunningham Kathryn A
Center for Addiction Research, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555-0616, USA.
Prog Brain Res. 2008;172:319-46. doi: 10.1016/S0079-6123(08)00916-3.
The serotonin (5-HT) neurotransmitter system provides fundamental modulatory regulation of the limbic-corticostriatal circuitry known to be vital in the development of addiction as well as the aspects of addiction that hinder recovery and contribute to relapse. Thus, components of the 5-HT system may provide novel targets for the development of pharmacological treatments for psychostimulant dependence, which is associated with significant aberrations in dopamine (DA) neurotransmission. Two key modulators of DA signalling within the limbic-corticostriatal circuit are the 5-HT(2A) receptor (5-HT(2A)R) and the 5-HT(2C)R. These receptors are known to control the neurochemical and behavioural effects of psychostimulants, and in particular the in vivo effects of cocaine. Pre-clinical studies indicate that 5-HT(2A)R antagonists and/or 5-HT(2C)R agonists may effectively reduce craving and/or relapse, and likewise, enhance abstinence, while 5-HT(2C)R agonists may also effectively reduce cocaine intake in active cocaine users. At present, the progression of studies to probe the effectiveness of 5-HT(2A)R and 5-HT(2C)R ligands in the clinical setting is hindered by a lack of available, selective 5-HT(2A)R antagonists or 5-HT(2C)R agonists for use in human cocaine abusers. However, a number of selective 5-HT(2)R ligands currently under development, or in early clinical trials for psychiatric and/or neurological disorders, may soon be available for translational studies to explore their effectiveness in modulating drug use and dependence.
血清素(5-羟色胺,5-HT)神经递质系统对边缘-皮质-纹状体回路起着基本的调节作用,该回路在成瘾的发展以及阻碍康复和导致复发的成瘾方面至关重要。因此,5-HT系统的组成部分可能为开发治疗精神兴奋剂依赖的药物提供新的靶点,精神兴奋剂依赖与多巴胺(DA)神经传递的显著异常有关。边缘-皮质-纹状体回路中DA信号的两个关键调节因子是5-HT(2A)受体(5-HT(2A)R)和5-HT(2C)受体(5-HT(2C)R)。已知这些受体可控制精神兴奋剂的神经化学和行为效应,尤其是可卡因的体内效应。临床前研究表明,5-HT(2A)R拮抗剂和/或5-HT(2C)R激动剂可能有效减少渴望和/或复发,同样,增强戒断,而5-HT(2C)R激动剂也可能有效减少活跃可卡因使用者的可卡因摄入量。目前,由于缺乏可用于人类可卡因滥用者的选择性5-HT(2A)R拮抗剂或5-HT(2C)R激动剂,阻碍了在临床环境中探究5-HT(2A)R和5-HT(2C)R配体有效性的研究进展。然而,目前正在开发或处于精神疾病和/或神经疾病早期临床试验阶段的一些选择性5-HT(2)R配体,可能很快可用于转化研究,以探索它们在调节药物使用和依赖方面的有效性。